Biology of Blood and Marrow Transplantation This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Multimodal Mobile Application to Address Sexual Dysfunction in Hematopoietic Stem Cell Transplant (HCT) Survivors
Sexual dysfunction is the most common complication affecting HCT survivors and is associated with worse patient-reported quality of life (QOL) and psychological distress. Yet, interventions to address sexual dysfunction in HCT survivors are lacking. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Areej R. El-Jawahri, Jennifer Barsky Reese, Lara Traeger, Don Dizon, Sharon Bober, Julie Vanderklish, Richard Andrew Newcomb, Zachariah DeFilipp, Dr. Yi-Bin Chen, Jennifer Temel Tags: 52 Source Type: research

Preservation of Pulmonary Function Following Hematopoietic Cell Transplant for Sickle Cell Disease: A STAR Study
We describe the trajectory of pulmonary function tests (PFTs) in a large group of SCD patients before and after HCT.Retrospective data was collected on 130 SCD patients ≥5 years old with follow-up ≥1 year post-HCT at 11 Sickle cell Transplant Advocacy and Research (STAR) Alliance centers. Patients included those that met height and PFT requirements per American Thoracic Society (ATS) criteria. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Fiona Horan, Glenda Bendiak, Allistair Abraham, Katie Liu, Scott Gillespie, Deepak Chellapandian, Rikin K Shah, Monica Bhatia, Sonali Chaudhury, Michael Eckrich, Dr. Jennifer Joi Jaroscak, Kimberly A. Kasow, Jennifer A. Krajewski, Alexander Ngwube, John H Tags: 53 Source Type: research

Relapse Incidence Post Unrelated Allogeneic Stem Cell Transplantation with Post-Transplant Cyclophosphamide (PTCy) in Patients with Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Post-transplant cyclophosphamide (PTCy) reduces chronic (c) graft-versus-host disease (GVHD) and thus may suppresses the graft-versus-leukemia (GVL) effect leading to increased relapse (RI). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Arnon Nagler, Maud Ngoya, Jacques-Emmanuel Galimard, Myriam Labopin, Wolfgang-Igor Blau, Nicolaus Kroger, Tobias Gedde-Dahl, Thomas Schroeder, David Burns, Urpu Salmenniemi, Alessandro Rambaldi, Goda Choi, R égis Peffault de Latour, Jan Vydra, Henrik Sen Tags: 54 Source Type: research

Abatacept and Ptcy with Cyclosporine or Sirolimus As Gvhd Prophylaxis in Haploidentical HCT: Understanding the Immunobiology in Improving the Outcome.
Abatacept (Abata, CTLA4Ig), an inhibitor of a key costimulation pathway has recently been approved for GVHD prophylaxis following unrelated donor HCT in combination with CNI/MTX. Since 2015, we had developed a novel protocol combining Abata and PTCy for HCT from haploidentical family donors. We analysed the impact of donor immunogenetics and immune reconstitution on the long-term outcome of 182 patients receiving HFD-HCT on this protocol. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Sarita Rani Jaiswal, Mahak Agarwal, Prakash Baligar, Hema Malini Aiyer, Bhudev C Das, Subhrajit Biswas, Suparno Chakrabarti Tags: 55 Source Type: research

Calcineurin Inhibitor-Free Graft-Versus-Host Disease (GVHD) Prophylaxis in Hematopoietic Cell Transplantation (HCT) with Myeloablative Conditioning Regimens (MAC) and HLA-Matched Donors: Long Term Follow up of BMT CTN 1301 Progress II Trial
The BMT CTN 1301 trial evaluated the role of calcineurin Inhibitor (CNI)-free approaches using T-cell depletion, either by ex vivo CD 34 selection or in vivo post-transplant cyclophosphamide (PTCy) without additional immune suppression compared to tacrolimus and methotrexate with bone marrow grafts and MAC. It demonstrated no difference in the primary composite endpoint of chronic GVHD, relapse-free survival (CRFS) and worse overall survival (OS) with CD-34 selection, despite low rates of chronic GVHD. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Marcelo C. Pasquini, Robert Soiffer, Brent Logan, Manmeet Kaur, Steven M. Devine, Nancy Geller, Sergio A. Giralt, Helen E. Heslop, Mary M. Horowitz, Mark R. Litzow, Adam Mendizabal, Lori S Muffly, Eneida Nemecek, Lynn C. O'Donnell, Johannes Schetelig, Ley Tags: 56 Source Type: research

Graft Vs Host Disease (GVHD) in Pediatric Hematopoietic Stem Cell Transplant (HCT) Recipients and Impact on Overall Survival: A CIBMTR Analysis
Recent multi-institutional studies of GVHD incidence and impact in pediatric patients are lacking. In this CIBMTR analysis, we compare the incidence of acute and chronic GVHD in pediatric patients by recipient age and compare overall survival (OS) and transplant related mortality (TRM) among patients with and without GVHD.We included 14,099 patients [7,582 with malignancy] ≤ 21 years receiving their first allogeneic HCT from 2002-2020. Recipient age was categorized as: 0-2 years (infants and toddlers, I/T), 3-12 years (school-aged, S/A), and 13-21 years (adolescent and young adult, AYA). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Miki Nishitani, Rudi-Ann Tamara Graham, Tao Wang, Jakob D DeVos, Stephanie J Lee, Stephen R. Spellman, Carrie L. Kitko, Margaret L. MacMillan, Zachariah DeFilipp, Christine N. Duncan, Muna Qayed Tags: 57 Source Type: research

Ibrutinib for Therapy of Steroid-Refractory Chronic Graft Vs. Host Disease: A Multicenter Real-World Analysis
Ibrutinib has been studied in steroid-refractory chronic graft vs. host disease (SR-cGVHD), yet the phase II trial that led to FDA approval contained 42 subjects, had restricted organ involvement, and median 2 prior lines of therapy. To expand on this evidence base, we conducted a multi-center real-world study.Eligible subjects had SR-cGVHD, did not have relapsed malignancy post-transplant, and were treated with ibrutinib after the FDA approval date (8/2017 onward). No other restrictions were placed for cGVHD organ sites/features, or prior lines of cGVHD therapy. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Joseph A. Pidala, Mary E.D. Flowers, Zachariah DeFilipp, Dr. Iskra Pusic, Muna Qayed, Anthony D Sung, Helen Tang, Hemalatha G. Rangarajan, Aaron Etra, Najla El Jurdi, Betty K. Hamilton, Mehdi Hamadani, Gulrayz Ahmed, Nosha Farhadfar, Dr. Corey Cutler, Kuo Tags: 58 Source Type: research

A Retrospective Analysis Comparing Orca-T to Post-Transplant Cyclophosphamide Based Allogeneic Hematopoietic Cell Transplant in Patients with Matched Unrelated Donors Receiving Myeloablative Conditioning
Identifying an allogeneic hematopoietic cell transplantation (HCT) modality that can reduce graft versus host disease (GvHD), lower non-relapse mortality (NRM), and increase relapse free survival (RFS) is the key to improving outcomes for patients with hematologic malignancies.Recently, the utilization of post-transplant cyclophosphamide (PTCy) as a prophylaxis against GvHD has increased; however, PTCy-based HCTs after myeloablative conditioning are associated with higher toxicities requiring prolonged hospitalization, NRM and relapse at 1-year. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Alexandra Gomez-Arteaga, Caspian Oliai, Sagar S. Patel, Jeremy Pantin, Arpita P Gandhi, Amandeep Salhotra, Dr. Bhagirathbhai Dholaria, Edmund K. Waller, Samer A. Srour, Anna Pavlova, Irene Agodoa, James Scott McClellan, Nathaniel B. Fernhoff, Mehrdad Abed Tags: 59 Source Type: research

The Mount Sinai Acute Gvhd International Consortium (MAGIC) Model: An Integrated Clinical and Biomarker Grading System for Acute Graft-Versus-Host Disease (GVHD)
Current acute graft-vs-host disease (GVHD) risk stratification systems use either biomarkers (e.g., Ann Arbor scores) or clinical symptoms (e.g., Minnesota risk), but not both. The Minnesota system (standard or high risk) lacks a low risk stratum needed for treatment de-escalation. This MAGIC study had two goals: to determine whether a risk model based on clinical symptoms alone could define three separate groups and to determine whether inclusion of biomarker risks could further improve the prediction of risk. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Yu Akahoshi, Nikolaos Spyrou, Daniela Weber, Paibel Ixia Aguayo-Hiraldo, Francis Ayuk, Udomsak Bunworasate, Hannah Choe, Matthias Eder, Aaron Etra, Stephan A. Grupp, Elizabeth O Hexner, William J. Hogan, Carrie L. Kitko, Sabrina Kraus, Pietro Merli, Muna Tags: 60 Source Type: research

131I-Apamistamab Improves Outcomes in Patients 65 Years and Older with Relapsed or Refractory AML
Older patients (pts) with relapsed or refractory acute myeloid leukemia (AML) have poor outcomes which have not improved over time. Only about 30% of AML pts aged 65 and older are offered treatment and the vast majority are not eligible for curative allogeneic hematopoietic cell transplant (HCT). Age as an independent risk factor for non-relapse mortality (NRM) exists in a continuum. 131I-apamistamab (Iomab-B), an anti-CD45 radioimmunoconjugate, safely delivers targeted radiation, allowing for myeloablation and eradication of leukemic cells. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Rajneesh Nath, Stuart Seropian, Boglarka Gyurkocza, Hannah Choe, Mark R. Litzow, Camille Abboud, Nebu Koshy, Patrick J. Stiff, Sunil H. Abhyankar, James Foran, Sameem Abedin, George L Chen, Zaid Al-Kadhimi, Partow Kebriaei, Mitchell Sabloff, Johnnie J. Or Tags: 61 Source Type: research

Excellent Outcomes Using a Non-Myeloablative Conditioning with Thiotepa and Post -Transplant Cyclophosphamide in Adults Undergoing a Matched Related Donor Bone Marrow Transplant for Severe Sickle Cell Disease
Allogeneic hematopoietic stem-cell transplantation (HSCT) is a validated curative therapy for sickle cell disease (SCD). The excellent outcomes of matched related donor (MRD) HSCT over the last 3 decades confirm the role of HLA-identical sibling BMT for SCD (PMID: 27965196). However, event-free survival (EFS) was lower with increasing age at transplantation (P (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Reem Alasbali, Mohsen Alzahrani, Saud Alhayli, Walid K. Rasheed, Karina Wilkerson, Riad El Fakih, Bader AlAhmari, Hadeel Samarkandi, Abdulwahab Albabtain, Ahmad Alotaibi, Syed O Ahmed, Ayman Saad, Hazzaa Alzahrani, Fahad Almohareb, Mahmoud Aljurf, Adetola Tags: 62 Source Type: research

Gemcitabine (Gem) /Clofarabine (Clo) /Busulfan (Bu) (GemCloBu): A New Myeloablative Conditioning Regimen with Reduced Toxicity and High Activity for Allogeneic Stem-Cell Transplant (alloSCT) for Aggressive Lymphomas
AlloSCT is used for patients (pts) with relapsed lymphomas pursuing a graft-vs-lymphoma effect. Reduced intensity conditioning regimens increased its safety but their insufficient cytotoxicity can cause aggressive lymphomas to progress rapidly after alloSCT. Seeking more active conditioning regimen we studied 2 nucleoside analogues (Gem  + Clo) followed by Bu, which showed synergy in lymphoma cell lines through DNA damage repair inhibition (Valdez, Leuk Lymphoma 2012). Those preclinical observations led us to clinically study GemCloBu for alloSCT in pts with aggressive lymphomas. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Jeremy Ramdial, Ben C. Valdez, Ruitao Lin, Peter Thall, Auston Wei, Chitra Hosing, Samer A. Srour, Uday R. Popat, Muzaffar H. Qazilbash, Amin M. Alousi, Melissa Barnett, Alison M. Gulbis, Terri Lynn Shigle, Elizabeth J. Shpall, Borje S. Andersson, Yago Ni Tags: 63 Source Type: research

Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic Malignancies
Older patients are often deemed unfit for myeloablative conditioning (MAC), which can increase the toxicity associated with transplant, and are relegated to treatment with reduced intensity conditioning (RIC) regimens, which result in a higher incidence of relapse.Orca-T is a high-precision cell therapy biologic that leverages highly purified, polyclonal donor regulatory T cells to control alloreactive immune responses. The specific subsets selected in the Orca-T manufacturing process retain cells with therapeutic benefit while removing those that pose potential risks, allowing for intensification of concomitant chemothera...
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Caspian Oliai, Jeremy Pantin, Rasmus T Hoeg, Lori S Muffly, Sagar S. Patel, Arpita Gandhi, Robert Lowsky, Amandeep Salhotra, Dr. Bhagirathbhai Dholaria, Edmund K. Waller, Samer A.MB SrourChB, Anna Pavlova, Nathaniel B. Fernhoff, Irene Agodoa, James Scott Tags: 64 Source Type: research

Phase II Trial of Reduced-Intensity Fludarabine, Melphalan 70 Mg/m2, and Total Body Irradiation Conditioning Results in Favorable Outcomes with Haploidentical Donor Peripheral Blood Stem Cell Transplant
Haploidentical (haplo) hematopoietic cell transplant (HCT) with post-transplant cyclophosphamide (PTCy) was initially developed with fludarabine/cyclophosphamide/total body irradiation (TBI) conditioning, resulting in low toxicity but high rates of relapse. We hypothesized that substituting melphalan 70 mg/m2 for cyclophosphamide in the conditioning regimen could successfully reduce the risk of relapse without substantially increasing non-relapse mortality (NRM), thus improving disease-free survival (DFS) in patients unfit for myeloablative conditioning. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Hany Elmariah, Jongphil Kim, Elizabeth DiMaggio, Rebecca Gonzalez, Jongphil Kim, Jongphil Kim, Asmita Mishra, Rawan G Faramand, Lia Elena Perez, Aleksandr Lazaryan, Farhad Khimani, Hien Liu, Leonel Ochoa, Dr. Michael L. Nieder, Nicholas Figura, Timothy Ro Tags: 65 Source Type: research

Targeted Myeloablative Radiation Using 131I-Apamistamab Prior to Allogeneic Hematopoietic Cell Transplant for Patients with R/R AML Results in Robust Engraftment
Most older patients (pts) with relapsed or refractory (r/r) AML cannot tolerate intensive treatment and are not eligible for curative allogeneic hematopoietic cell transplant (HCT). Iomab-B (131I-apamistamab), an anti-CD45 radioimmunoconjugate, safely delivers targeted radiation to hematopoietic cells, allowing for myeloablation and eradication of leukemic cells. Iomab-B based induction and conditioning can provide these pts with access to HCT. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Hannah Choe, Dr. Rajneesh Nath, Dr. Stuart E. Seropian, Mark R. Litzow, Camille Abboud, Nebu Koshy, Patrick J. Stiff, Benjamin Tomlinson, Sunil H. Abhyankar, James Foran, Sameem Abedin, George L Chen, Zaid Al-Kadhimi, Partow Kebriaei, Mitchell Sabloff, Jo Tags: 66 Source Type: research